Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valanafusp alfa - ArmaGen Technologies

Next Previous
Drug Profile

Valanafusp alfa - ArmaGen Technologies

Alternative Names: AGT-181; cTfRMAb-IDUA murine fusion protein; HIRMAb-IDUA; IgG-alpha-L-iduronidase fusion protein; IgG-IDUA fusion protein; Recombinant human insulin receptor monoclonal antibody-fused alpha-L-iduronidase; Valanafusp; Valanafusp Alpha - ArmaGen

Latest Information Update: 29 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ArmaGen Technologies
  • Class Immunoglobulin fusion proteins; Monoclonal antibodies
  • Mechanism of Action Iduronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mucopolysaccharidosis I

Most Recent Events

  • 29 Sep 2021 Phase II development for Mucopolysaccharidosis I (In children) is still ongoing in Brazil (IV) (ArmaGen Technologies website, September 2021)
  • 08 Sep 2021 No development reported - Phase-I/II for Mucopolysaccharidosis I in USA (IV)
  • 08 Sep 2021 No development reported - Phase-II for Mucopolysaccharidosis I (In children) in Brazil (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top